Juno Therapeutics, Inc., a Seattle, WA-based biotechnology company focused on advancing novel immunotherapies for cancer, closed a $134m Series B financing.
This round included new investments by ten public mutual funds and healthcare-focused funds as well as by major prior investors.
The company intends to use the funds to continue advancing its chimeric antigen receptor (CAR) and T-cell receptor (TCR) pipeline, including CAR T-cell therapies directed against CD19 currently in phase 1/2 trials and solid tumor targets.
Launched in December 2013 and led by Hans Bishop, CEO, Juno Juno is a clinical stage company that brings together innovative technologies from Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center and Seattle Children’s Research Institute – to advance a broad pipeline of potential curative immunotherapy treatments.
The company will develop two distinct and complementary platforms – chimeric antigen receptors (CARs) and T-cell receptors (TCRs). The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with current chemotherapeutics.
Juno had closed its $176M Series A in April (read here).